E.Q. Wu

893 total citations
39 papers, 694 citations indexed

About

E.Q. Wu is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, E.Q. Wu has authored 39 papers receiving a total of 694 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in E.Q. Wu's work include Inflammatory Bowel Disease (4 papers), Gastroesophageal reflux and treatments (3 papers) and Stroke Rehabilitation and Recovery (3 papers). E.Q. Wu is often cited by papers focused on Inflammatory Bowel Disease (4 papers), Gastroesophageal reflux and treatments (3 papers) and Stroke Rehabilitation and Recovery (3 papers). E.Q. Wu collaborates with scholars based in United States, United Kingdom and Germany. E.Q. Wu's co-authors include James Signorovitch, Parvez Mulani, A. Guérin, Andrew P. Yu, Kathleen G. Lomax, Dendy Macaulay, Yan Yan, Markus K. Diener, J. Chao and Omar Dabbous and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Annals of Oncology.

In The Last Decade

E.Q. Wu

39 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.Q. Wu United States 12 201 175 171 121 99 39 694
Rajesh Khadgawat India 17 229 1.1× 188 1.1× 105 0.6× 86 0.7× 214 2.2× 67 807
Tung‐Min Yu Taiwan 18 149 0.7× 165 0.9× 74 0.4× 12 0.1× 65 0.7× 68 911
Jesper Rye Andersen Denmark 10 206 1.0× 125 0.7× 128 0.7× 38 0.3× 273 2.8× 22 647
Bin Xia China 12 133 0.7× 95 0.5× 40 0.2× 94 0.8× 28 0.3× 44 512
G Biesenbach Austria 17 320 1.6× 97 0.6× 64 0.4× 36 0.3× 234 2.4× 61 969
Julio Messer United States 7 264 1.3× 112 0.6× 71 0.4× 87 0.7× 42 0.4× 11 508
Stephanie Davis United States 11 274 1.4× 35 0.2× 101 0.6× 116 1.0× 309 3.1× 23 838
Benan Kasapoğlu Türkiye 15 125 0.6× 187 1.1× 40 0.2× 37 0.3× 78 0.8× 45 633
Mats Palmér Sweden 12 297 1.5× 43 0.2× 267 1.6× 33 0.3× 223 2.3× 15 832
Brandon Orr‐Walker New Zealand 18 141 0.7× 89 0.5× 79 0.5× 17 0.1× 242 2.4× 43 1.1k

Countries citing papers authored by E.Q. Wu

Since Specialization
Citations

This map shows the geographic impact of E.Q. Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.Q. Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.Q. Wu more than expected).

Fields of papers citing papers by E.Q. Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.Q. Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.Q. Wu. The network helps show where E.Q. Wu may publish in the future.

Co-authorship network of co-authors of E.Q. Wu

This figure shows the co-authorship network connecting the top 25 collaborators of E.Q. Wu. A scholar is included among the top collaborators of E.Q. Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.Q. Wu. E.Q. Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Stein, Eytan M., Dominick Latrémouille-Viau, Sherry Shi, et al.. (2020). PDG20 HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS. Value in Health. 23. S132–S133. 1 indexed citations
3.
Zhou, Jiewen, et al.. (2020). PND5 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in the United States. Value in Health Regional Issues. 22. S75–S75. 2 indexed citations
4.
Dabbous, Omar, et al.. (2019). RO2 ASSESSING THE RELATIONSHIP BETWEEN LIFELONG VALUE AND PRICING FOR ORPHAN DRUGS IN ULTRA-RARE DISEASES. Value in Health. 22. S388–S388. 1 indexed citations
5.
Guérin, A., Medha Sasané, Kenneth W. Culver, et al.. (2016). The economic burden of brain metastasis among lung cancer patients in the United States. Journal of Medical Economics. 19(5). 526–536. 37 indexed citations
6.
Yim, Yeun Mi, A. Guérin, Raluca Ionescu‐Ittu, et al.. (2016). Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC). Annals of Oncology. 27. vi424–vi424. 1 indexed citations
7.
8.
Soliman, Ahmed M., Mahesh Fuldeore, Hongbo Yang, et al.. (2014). Treatment patterns among US women diagnosed with endometriosis: a retrospective claims analyses pre- and post-diagnosis. Fertility and Sterility. 102(3). e290–e290. 1 indexed citations
9.
Wu, E.Q., et al.. (2014). Costs Of Venous Thromboembolism (Vte) Among Hospitalized Patients In China. Value in Health. 17(3). A109–A109. 1 indexed citations
10.
Macalalad, Alexander R., et al.. (2014). BM-19 * SYMPTOMATIC AND ECONOMIC BURDEN OF BRAIN METASTASES IN PATIENTS WITH ALK+ NSCLC. Neuro-Oncology. 16(suppl 5). v36–v36. 3 indexed citations
11.
Switzer, Julie A., et al.. (2012). Cost-Effectiveness of Hub-and-Spoke Telestroke Networks for the Management of Acute Ischemic Stroke (P05.243). Neurology. 78(Meeting Abstracts 1). P05.243–P05.243. 3 indexed citations
12.
Yang, Heidi Y., Jing Wu, Yilin Zheng, et al.. (2012). PRS16 Economic Burden Associated with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in China. Value in Health. 15(4). A54–A54. 1 indexed citations
13.
Zheng, Yilin, et al.. (2012). PDB40 Economic Burden of Type 2 Diabetes Mellitus in China. Value in Health. 15(4). A177–A177. 2 indexed citations
14.
Signorovitch, James, et al.. (2012). Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non‐insulin antidiabetes drugs. Diabetes Obesity and Metabolism. 15(4). 335–341. 95 indexed citations
15.
Setyawan, Juliana, P. Hodgkins, A. Guérin, et al.. (2012). Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis. Neuropsychiatrie de l Enfance et de l Adolescence. 60(5). S261–S261. 1 indexed citations
16.
17.
18.
Velde, Nathalie van der, E.Q. Wu, Amy Guo, et al.. (2010). The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate Cancer and Prostatic Diseases. 14(1). 79–84. 10 indexed citations
19.
Lichtiger, Simon, Douglas C. Wolf, D. H. Present, et al.. (2010). The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Alimentary Pharmacology & Therapeutics. 32(10). 1228–1239. 149 indexed citations
20.
Wu, E.Q., et al.. (2007). Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Current Medical Research and Opinion. 23(9). 2035–2042. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajesh Khadgawat Breakdown of academic impact, for papers by Tung‐Min Yu Breakdown of academic impact, for papers by Jesper Rye Andersen Breakdown of academic impact, for papers by Bin Xia Breakdown of academic impact, for papers by G Biesenbach Breakdown of academic impact, for papers by Julio Messer Breakdown of academic impact, for papers by Stephanie Davis Breakdown of academic impact, for papers by Benan Kasapoğlu Breakdown of academic impact, for papers by Mats Palmér Breakdown of academic impact, for papers by Brandon Orr‐Walker
Rankless by CCL
2026